Last updated: February 24, 2026
What is NDC 46122-0462?
NDC 46122-0462 is the National Drug Code for Imetelstat, an investigational telomerase inhibitor developed by Geron Corporation. Used in pre-approval contexts, primarily under clinical trials, Imetelstat targets certain hematologic malignancies, including myelofibrosis and certain leukemias.
Market Landscape
Current Status
Imetelstat remains an investigational drug in Phase 2/Phase 3 clinical trials. It has not received FDA or other major regulatory approvals for commercial distribution. Its market potential hinges on successful trial outcomes and eventual regulatory approval.
Competitive Environment
- Major competitors: Ruxolitinib (Novartis), fed for myelofibrosis.
- Pipeline candidates: Multiple telomerase inhibitors in development, but none have yet reached approval stages comparable to marketed therapies.
- Market size estimates: For myelofibrosis, global sales are estimated to reach $2 billion annually (as of 2022), with increasing incidence rates projected at 4-5% annually[1].
Regulatory and Development Highlights
- Phase 3 trials: Ongoing, with top-line data anticipated over the next 12-24 months.
- Trial outcomes impact: Positive results could establish Imetelstat as a standard treatment, affecting market size and pricing.
Price Projections
Factors Influencing Pricing
- Development stage: As an experimental drug, pricing is speculative until regulatory approval.
- Market penetration: Effectiveness, safety profile, and comparative efficacy influence pricing.
- Manufacturing costs: Biologics and complex small molecules tend to have high production costs.
- Reimbursement environment: Payer acceptance and potential for premium pricing based on clinical benefit.
Range of Price Estimates
| Scenario |
Price Range (per treatment cycle) |
Assumptions |
Source |
| Conservative |
$50,000 – $80,000 |
Limited market adoption, high competition from existing drugs |
Based on comparable myelofibrosis therapies (e.g., ruxolitinib) |
| Moderate |
$80,000 – $150,000 |
After regulatory approval, initial pricing aligned with current standards |
Based on pricing for other novel treatments (e.g., Fedratinib) |
| Optimistic |
$150,000 – $250,000 |
Breakthrough designation, high unmet need, premium pricing |
Based on premium biologic pricing power, unmet clinical need |
Influencing Factors
- Clinical outcomes: Improved survival or symptom management may justify premium prices.
- Treatment regimen: Monotherapy versus combination therapy impacts total cost.
- Market approval timeline: Delay or failure limits revenue potential and reduces effective pricing.
Revenue and Market Share Projections
| Year |
Estimated Units Sold |
Revenue Estimates |
Market Share (%) |
Assumptions |
| 2024 |
2,000 – 5,000 |
$100M – $300M |
5 – 10% |
Based on early commercialization if approved by late 2023 |
| 2025 |
10,000 – 20,000 |
$800M – $3B |
15 – 20% |
As adoption increases, with expanded indications |
| 2026 |
20,000 – 40,000 |
$2B – $5B |
25 – 30% |
Assuming successful trials and broader indications |
Risks and Opportunities
Risks
- Clinical failure: Unfavorable trial data could lead to abandonment.
- Regulatory delays or rejection: Could diminish market prospects.
- Market competition: Better-tolerated or more effective therapies could constrain pricing and share.
Opportunities
- Unmet medical needs: Targeting difficult-to-treat malignancies offers a potential premium.
- Regulatory incentives: Breakthrough therapy or orphan drug status could accelerate approval and support higher prices.
- Partnerships: Licensing or co-development arrangements could expand market access.
Key Takeaways
- NDC 46122-0462 (Imetelstat) remains in clinical development; market entry and pricing depend heavily on trial outcomes.
- Estimated treatment cycle prices post-approval range from $80,000 to over $200,000, with higher prices justified by clinical benefits.
- Market size could reach several billion dollars annually in the US and Europe if approved widely and adopted early.
- Competitive landscape includes existing drugs like ruxolitinib, with innovation and clinical efficacy driving premium pricing.
- Regulatory events and trial results over the next 12-24 months will determine market trajectory.
FAQs
Q1: When could Imetelstat reach the market?
A1: If Phase 3 trial results are positive and filings occur in 2024, regulatory approval might happen by 2025-2026.
Q2: What factors could enable premium pricing for Imetelstat?
A2: Demonstrating superior efficacy, safety, or addressing unmet medical needs influences premium pricing. Orphan drug designation also supports higher prices.
Q3: How does Imetelstat compare to existing treatments?
A3: It is being developed to target hematologic malignancies with potentially different mechanisms of action, possibly benefiting patients resistant or intolerant to current therapies.
Q4: Which markets will be most impacted?
A4: The US accounts for the largest market share, followed by Europe and select Asian countries, depending on approval and reimbursement policies.
Q5: What risks could affect market entry?
A5: Clinical trial failure, regulatory setbacks, patent challenges, and pricing pressures.
Citations
[1] GlobalData. (2022). Hematologic Malignancies Market Report.
